3:00
EBMT 2018: Updates on advanced Hodgkin lymphoma treatment
Martin Hutchings
1:31
PEP-C for lymphoma palliative care: a regional experience in the UK
George Follows
1:31
ABVD vs. escBEACOPP in HL: a 10-year study
George Follows
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:09
ECHELON-1 trial data from ASH 2017: controversies and clinical translation
Graham Collins
2:30
New antibody-drug conjugates for lymphoma
Graham Collins
iwNHL 2017: T-cell lymphomas, Hodgkin’s lymphoma, immunotherapy and epigenetics
Francesco d'Amore et al.
1:47
Latest research in Hodgkin lymphoma
Anas Younes
5:37
Key abstracts being presented at ASH 2017
Anas Younes
1:15
The future for the treatment of Hodgkin lymphoma
Stephen Ansell
1:28
CAR-T cell therapy debate: the future of lymphoma treatment?
Graham Collins
2:30
New lymphoma drug studies show promise
Graham Collins
5:52
Revolutionary immunotherapy for lymphoma
Graham Collins
2:27
What are the challenges of integrating therapy around autologous transplantation?
John Kuruvilla
5:01
Overcoming toxicities when combining PI3K inhibitors with other treatments
Nathan Fowler
1:40
Checkpoint inhibitors in Hodgkin lymphoma
John Kuruvilla
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals